SCM
CYTK icon

Superstring Capital Management’s Cytokinetics CYTK Stock Holding History

Superstring Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-61,103
Closed -$2.02M – 36
2025
Q2 		$2.02M Sell
61,103
-11,889
-16% -$414K 2.39% 16
2025
Q1 		$2.93M Sell
72,992
-56,397
-44% -$2.59M 3.49% 11
2024
Q4 		$6.09M Sell
129,389
-86,409
-40% -$4.49M 5.27% 7
2024
Q3 		$11.4M Buy
215,798
+28,165
+15% +$1.57M 9.97% 2
2024
Q2 		$10.2M Sell
187,633
-91,282
-33% -$5.51M 12.82% 1
2024
Q1 		$19.6M Buy
278,915
+101,312
+57% +$7.84M 12.93% 1
2023
Q4 		$14.8M Buy
+177,603
New +$6.43M 10.58% 2

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Superstring Capital Management's CYTK Position: Q3 2025 in Review

Superstring Capital Management sold out of Cytokinetics (CYTK) in Q3 2025, closing a stake of 61,103 shares — an estimated $2.02M sold.

Superstring Capital Management first reported a position in CYTK in Q4 2023 and held it in 7 quarters. The position peaked at $19.6M in Q1 2024. 380 funds tracked by Wall St. Rank hold CYTK as of Q3 2025.

  • Superstring Capital Management reported no remaining Cytokinetics position as of Q3 2025 after selling out during the quarter.
  • Superstring Capital Management sold 61,103 Cytokinetics shares in Q3 2025, an estimated $2.02M.
  • Superstring Capital Management first reported a position in Cytokinetics in Q4 2023 and held it in 7 quarters.
  • Superstring Capital Management's Cytokinetics position peaked at $19.6M in Q1 2024.
  • 380 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2025.

Based on Superstring Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.